Companies That Had Their IPO in 2025
This page contains links to our partners. We may be compensated when a link is clicked. Read the disclosures to learn more.
Here’s an active list of companies that had their IPO in 2025. This list includes only the most notable IPOs of the year, not a complete list of IPOs.
See also:
1. Venture Global IPO (01/24/2025)
The Venture Global IPO completed on Friday, January 24th, 2025. The IPO price was $25. The stock opened for trading at $24.05 per share at 12:50 pm ET. Shares closed the day at $24.
Venture Global is an Arlington, Virginia-based private company that produces and exports liquefied natural gas (LNG), primarily out of Louisiana.
The company released its SEC S-1 filing to the public on December 20th
Venture Global stock now trades on the NYSE under the stock symbol “VG”.
Final IPO terms were as follows:
- Shares: 70,000,000
- Price: $25 per share
- Raise: $1.75 billion
- Market Cap: $65 billion
- Pricing Date: January 23rd, 2025
- IPO Date: January 24th, 2025
Its main business revolves around developing, owning, and operating LNG facilities along the Gulf Coast, with a focus on providing low-cost and long-term LNG supply to global markets.
Founded in 2013 by Co-CEOs Michael Sabel and Bob Pender, the company leverages low-cost natural gas from U.S. shale basins to meet international energy demands.
Venture Global LNG employs modular technology in its facilities to enhance efficiency and reduce costs, a key differentiator in the competitive LNG market.
Its flagship projects include Calcasieu Pass LNG, Plaquemines LNG, and others under development, targeting high-demand regions like Asia and Europe.
2. Beta Bionics IPO (01/30/2025)
The Beta Bionics IPO completed on Thursday, January 30th, 2025. The IPO price was $17. The stock opened for trading at $22 per share.
Beta Bionics is a medical device maker with an FDA-approved automated insulin pump for people with Type 1 Diabetes.
It’s insulin pump (the iLet “bionic pancreas”) competes with Insulet, Tandem Diabetes, and Medtronic, which collectively command 96% of the market. But Beta Bionic’s devices require only simplified user input parameters to enable better blood sugar control for patients still relying on syringe injections.
The iLet insulin pump integrates with CGMs made my Abbott and Dexcom.
The company filed for an IPO on January 6th and updated the terms on January 22nd.
- Shares: 10,000,000
- Price: $17 per share
- Raise: $204 million
- Market Cap: $700 million
- Symbol: BBNX
- Opening Trade: $22
- IPO Date: January 30th, 2025
This IPO was less than a $1 billion deal, a size Access IPOs doesn’t usually pay attention to. But I know this space well because my son has Type 1 Diabetes and uses an insulin pump (OmniPod 5).
Managing Type 1 Diabetes challenges our family every day. These pumps are life-changing. The Beta Bionics pump will fill a gap where there’s an unmet need, simplifying insulin delivery for many people not using a pump yet.
Better blood sugar management leads to better healthcare outcomes across the board. Insurers should encourage the use of these products and cover them without question or hesitation.
3. CoreWeave IPO (03/28/2025)
The CoreWeave IPO date was Friday, March 28th, 2025. The IPO price was $40. The stock opened for trading at $39 per share and closed on the first day of trading at $40 per share.
CoreWeave is a cloud infrastructure company based in Roseland, New Jersey. It provides “a massive scale of GPUs on top of the industry’s fastest and most flexible infrastructure,” helping to fuel the AI arms race.
The company is most notable for offering cloud access to Nvidia’s HGX H100 chips which provide superior GPU processing for training AI large language models (LLM) and AI imaging applications.
CoreWeave’s founders began stocking up on processing chips to mine Ethereum before the AI boom, which kicked off after the release of OpenAI’s ChatGPT.
It left Wall Street for the New Jersey suburbs and began selling access to its GPUs when cryptocurrencies became unpopular.
The startup claims to be two years ahead of other cloud providers. It can provide AI startups with the appropriate level of computing needed for complex models.
CoreWeave conducted a tender offer at a $23 billion valuation in September 2024.
Read more about the CoreWeave IPO.
* This is a testimonial in partnership with Fundrise, Hiive, and other affiliate partners. We earn a commission from partner links on AccessIPOs.com. All opinions are my own. If you sign up with one of our partners through certain on this website, Access IPOs will be compensated at no additional cost to the reader. See the full disclosure here. Risk Statement: Investing in IPOs and pre-IPO startups involves significant risk. Do not invest in companies based solely on what is included in this article. Only invest in IPOs and pre-IPO companies with money you can afford to lose. Access IPOs is for informational purposes only. Mentions of specific investments should not be construed as financial advice. Conduct personalized research and consider consulting with an investment advisor before investing.